Literature DB >> 33670004

Analgesic Opioid Misuse and Opioid Use Disorder among Patients with Chronic Non-Cancer Pain and Prescribed Opioids in a Pain Centre in France.

Morgane Guillou-Landreat1,2,3,4, Bertrand Quinio4, Jean Yves Le Reste2, Delphine Le Goff2, Jérôme Fonsecca2, Marie Grall-Bronnec1,2,3,5, Antoine Dany2.   

Abstract

(1) Background: Chronic non-cancer pain (CNCP) remains a public health challenge around the world. Opioids (PO) have been increasingly used in the treatment of CNCP in the last 20 years. This study aimed to assess the prevalence of opioid misuse and prescribed-opioid use disorder (p-OUD) among patients with CNCP in a pain centre in France, and to analyse risk factors for moderate or severe p-OUD. (2) Method: A cross-sectional study was conducted, including patients consulting for pain management in the pain centre of Brest University Hospital. A self-questionnaire was administered (sociodemographic data, medical data, PO misuse, and p-OUD according the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5) criteria). Descriptive, univariate, and multivariate analyses were conducted, together with a principal component analysis, in order to identify factors associated with p-OUD. (3)
Results: In total, 115 patients were included, the majority of whom were women, with a mean age of 52 years old [18-82]; 64.3% (n = 74) had a current prescription for opioid analgesics (weak or strong). In this group, 56.7% (n = 42) had no or only mild p-OUD and 43.3% (n = 32) had current moderate or severe p-OUD. Patients with moderate or severe p-OUD were more likely to have a current antidepressant prescription, to have had psychotherapy, to currently use strong opioids and oxycodone, and to report taking more frequent doses than prescribed and feeling dependent. (4) Conclusions: We showed that the prevalence of current moderate/severe p-OUD concerned 43.3% of the patients with a CNCP seeking treatment in a pain centre. According to these results, several measures are relevant in managing p-OUD among patients with CNCP.

Entities:  

Keywords:  chronic non-cancer pain; opioid misuse; opioid use disorder; prescribed opioids

Year:  2021        PMID: 33670004      PMCID: PMC7926319          DOI: 10.3390/ijerph18042097

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  51 in total

1.  Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment.

Authors:  Harald Breivik; Beverly Collett; Vittorio Ventafridda; Rob Cohen; Derek Gallacher
Journal:  Eur J Pain       Date:  2005-08-10       Impact factor: 3.931

2.  Prescription opioid analgesic use in France: Trends and impact on morbidity-mortality.

Authors:  C Chenaf; J-L Kaboré; J Delorme; B Pereira; A Mulliez; M Zenut; N Delage; D Ardid; A Eschalier; N Authier
Journal:  Eur J Pain       Date:  2018-08-20       Impact factor: 3.931

3.  Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern.

Authors:  Hannu Alho; Maurice Dematteis; Danilo Lembo; Icro Maremmani; Carlos Roncero; Lorenzo Somaini
Journal:  Int J Drug Policy       Date:  2019-12-16

4.  High Prevalence of Misuse of Prescribed Opioid Analgesics in Patients with Chronic Non-Cancer Pain.

Authors:  Céline Eiden; Patrick Ginies; Erika Nogue; Yohan Damdjy; Marie-Christine Picot; Hélène Donnadieu-Rigole; Hélène Peyrière
Journal:  J Psychoactive Drugs       Date:  2019-05-31

5.  Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 vs. DSM-4 diagnostic criteria.

Authors:  Joseph A Boscarino; Margaret R Rukstalis; Stuart N Hoffman; John J Han; Porat M Erlich; Stephen Ross; Glenn S Gerhard; Walter F Stewart
Journal:  J Addict Dis       Date:  2011 Jul-Sep

6.  Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R).

Authors:  Stephen F Butler; Kathrine Fernandez; Christine Benoit; Simon H Budman; Robert N Jamison
Journal:  J Pain       Date:  2008-01-22       Impact factor: 5.820

Review 7.  Consensus and Controversies Between Pain and Addiction Experts on the Prevention, Diagnosis, and Management of Prescription Opioid Use Disorder.

Authors:  Mark Kraus; Nicholas Lintzeris; Arun Bhaskar; Hannu Alho; Eli Alon; Didier Bouhassira; Gonzalo Haro; Oscar D'Agnone; Maurice Dematteis; Kai-Uwe Kern; Icro Maremmani; Serge Perrot; Reinhard Sittl; Kaitlin Pellicano
Journal:  J Addict Med       Date:  2020 Jan/Feb       Impact factor: 3.702

8.  Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study.

Authors:  Louisa Degenhardt; Raimondo Bruno; Nicholas Lintzeris; Wayne Hall; Suzanne Nielsen; Briony Larance; Milton Cohen; Gabrielle Campbell
Journal:  Lancet Psychiatry       Date:  2015-03-31       Impact factor: 27.083

9.  Prescription Opioid Misuse Index: a brief questionnaire to assess misuse.

Authors:  Janet S Knisely; Martha J Wunsch; Karen L Cropsey; Eleanor D Campbell
Journal:  J Subst Abuse Treat       Date:  2008-07-26

Review 10.  Long-term opioid management for chronic noncancer pain.

Authors:  Meredith Noble; Jonathan R Treadwell; Stephen J Tregear; Vivian H Coates; Philip J Wiffen; Clarisse Akafomo; Karen M Schoelles
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20
View more
  2 in total

1.  An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine.

Authors:  Consalvo Mattia; Livio Luongo; Massimo Innamorato; Luca Melis; Michele Sofia; Lucia Zappi; Filomena Puntillo
Journal:  J Pain Res       Date:  2021-10-11       Impact factor: 3.133

2.  Cross-sectional study of the prevalence of prescription opioids misuse in French patients with chronic non-cancer pain: An update with the French version of the POMI scale.

Authors:  Nicolas Kerckhove; Noémie Delage; Célian Bertin; Emmanuelle Kuhn; Nathalie Cantagrel; Caroline Vigneau; Jessica Delorme; Céline Lambert; Bruno Pereira; Chouki Chenaf; Nicolas Authier
Journal:  Front Pharmacol       Date:  2022-09-05       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.